**Patient Name** Mrs. KIRAN MEENA Lab No 4059434 UHID 40022528 **Collection Date** 26/10/2024 10:50AM

26/10/2024 10:54AM Age/Gender 30 Yrs/Female **Receiving Date Report Date IP/OP Location** O-OPD 26/10/2024 6:23PM

**Referred By** Dr. EHS CONSULTANT **Report Status** Final

105.0

Mobile No. 9950555133

## **BIOCHEMISTRY**

mg/dl

**Test Name** Result Unit **Biological Ref. Range BLOOD GLUCOSE (FASTING)** Sample: Fl. Plasma **BLOOD GLUCOSE (FASTING)** 71 - 109

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

**BLOOD GLUCOSE (PP)** Sample: PLASMA

BLOOD GLUCOSE (PP) 91.4 Non - Diabetic: - < 140 mg/dl mg/dl

Pre - Diabetic: - 140-199 mg/dl Diabetic: ->=200 mg/dl

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

**THYROID T3 T4 TSH** Sample: Serum

Т3	1.360	ng/mL	0.970 - 1.690
T4	7.76	ug/dl	5.53 - 11.00
TSH	3.39	μIU/mL	0.27 - 4.20

**RESULT ENTERED BY: SUNIL EHS** 

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 1 Of 8

Patient Name	Mrs. KIRAN MEENA	Lab No	4059434
UHID	40022528	Collection Date	26/10/2024 10:50AM
Age/Gender IP/OP Location	30 Yrs/Female	Receiving Date	26/10/2024 10:54AM
	O-OPD	Report Date	26/10/2024 6:23PM
Referred By Mobile No.	Dr. EHS CONSULTANT 9950555133	Report Status	Final

#### **BIOCHEMISTRY**

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in thediagnosis of T3-hyperthyroidism the detection of early stages ofhyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

Interpretation: - The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH levels.

LFT (LIVER FUNCTION TEST)				Sample: Serum
BILIRUBIN TOTAL	1.14	mg/dl	0.00 - 1.20	
BILIRUBIN INDIRECT	0.79	mg/dl	0.20 - 1.00	
BILIRUBIN DIRECT	0.35 H	mg/dl	0.00 - 0.30	
SGOT	20.4	U/L	0.0 - 32.0	
SGPT	16.6	U/L	0.0 - 33.0	

g/dl

g/dl

6.6 - 8.7

3.5 - 5.2

**GLOBULIN** 3.0 1.8 - 3.6 ALKALINE PHOSPHATASE 54 U/L 35 - 104 A/G RATIO 1.5 Ratio 1.5 - 2.5 **GGTP** 8.0 U/L 0.0 - 40.0

7.6

4.6

**RESULT ENTERED BY: SUNIL EHS** 

TOTAL PROTEIN

ALBUMIN

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 2 Of 8

**Patient Name** Mrs. KIRAN MEENA Lab No 4059434 UHID **Collection Date** 26/10/2024 10:50AM 40022528 26/10/2024 10:54AM Age/Gender **Receiving Date** 30 Yrs/Female Report Date O-OPD **IP/OP Location** 26/10/2024 6:23PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 9950555133

#### **BIOCHEMISTRY**

**BILIRUBIN TOTAL** :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILIRUBIN DIRECT :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS: - Method: Bivret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder.

ALBUMIN: - Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status.

ALKALINE PHOSPHATASE: - Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE: - Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

#### LIPID PROFILE

TOTAL CHOLESTEROL	138.5		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	54.0		High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	79.7		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	17	mg/dl	10 - 50
TRIGLYCERIDES	86.9		Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl
CHOLESTEROL/HDL RATIO	3	%	

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

Lab No **Patient Name** Mrs. KIRAN MEENA 4059434 **Collection Date** 26/10/2024 10:50AM UHID 40022528 26/10/2024 10:54AM Age/Gender **Receiving Date** 30 Yrs/Female Report Date O-OPD **IP/OP Location** 26/10/2024 6:23PM

Referred By Dr. EHS CONSULTANT Report Status Final

Mobile No. 9950555133

#### **BIOCHEMISTRY**

CHOLESTEROL TOTAL: - Method: CHOD-PAP enzymatic colorimetric assay. Interpretation: - The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders. HDL CHOLESTEROL: - Method: -Homogenous enzymetic colorimetric method. Interpretation: -HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease. LDL CHOLESTEROL: - Method: Homogenous enzymatic colorimetric assay. Interpretation: -LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are synthesized in the liver. CHOLESTEROL VLDL: - Method: VLDL

TRIGLYCERIDES: - Method: GPO-PAP enzymatic colorimetric assay. Interpretation: - High triglycerde levels also occur in various diseases of liver, kidneys and pancreas. DM, nephrosis, liver obstruction. CHOLESTEROL/HDL RATIO: - Method: Cholesterol/HDL Ratio Calculative

Sample: Serum

UREA	20.90	mg/dl	16.60 - 48.50
BUN	10	mg/dl	6 - 20
CREATININE	0.54	mg/dl	0.50 - 0.90
SODIUM	141	mmol/L	136 - 145
POTASSIUM	4.94	mmol/L	3.50 - 5.50
CHLORIDE	105.7	mmol/L	98 - 107
URIC ACID	3.5	mg/dl	2.4 - 5.7
CALCIUM	9.80	mg/dl	8.60 - 10.00

CREATININE - SERUM :- Method: -Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease.

URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.

SODIUM:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake andkidney reabsorption.

POTASSIUM:- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure.

CHLORIDE - SERUM: - Method: ISE electrode. Interpretation: - Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, qlomerularnephritis and UTI.

CALCIUM TOTAL: - Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usually associated with hypercalcemia. Increased serum calcium levels may also be observed in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

Sample: WHOLE BLOOD EDTA

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 4 Of 8

Patient Name Mrs. KIRAN MEENA Lab No 4059434 UHID 40022528 **Collection Date** 26/10/2024 10:50AM 26/10/2024 10:54AM Age/Gender 30 Yrs/Female **Receiving Date Report Date IP/OP Location** O-OPD 26/10/2024 6:23PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final 9950555133 Mobile No.

**BIOCHEMISTRY** 

HBA1C 4.9 % <5.7% Nondiabetic

5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes

Known Diabetic Patients
< 7 % Excellent Control
7 - 8 % Good Control
> 8 % Poor Control

Method: - Turbidimetric inhibition immunoassay (TINIA), Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. The approximate relationship between HbA1C and mean blood glucose values during the preceding 2 to 3 months.

RESULT ENTERED BY : SUNIL EHS

Dr. ABHINAY VERMA

**Patient Name** Mrs. KIRAN MEENA Lab No 4059434 UHID 40022528 **Collection Date** 26/10/2024 10:50AM 26/10/2024 10:54AM Age/Gender **Receiving Date** 30 Yrs/Female **Report Date IP/OP Location** O-OPD 26/10/2024 6:23PM

**Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9950555133

## **BLOOD BANK INVESTIGATION**

**Biological Ref. Range Test Name** Result Unit

"AB" Rh Positive **BLOOD GROUPING** 

1. Both forward and reverse grouping performed.
2. Test conducted on EDTA whole blood.

**RESULT ENTERED BY: SUNIL EHS** 

Dr. ABHINAY VERMA

**Patient Name** Mrs. KIRAN MEENA Lab No 4059434 UHID 40022528 **Collection Date** 26/10/2024 10:50AM 26/10/2024 10:54AM Age/Gender 30 Yrs/Female **Receiving Date** Report Date **IP/OP Location** O-OPD 26/10/2024 6:23PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final

Mobile No. 9950555133

#### **HEMATOLOGY**

Test Name	Result	Unit	Biological Ref. Rang	ge
				Sample: WHOLE BLOOD EDTA
HAEMOGLOBIN	12.5	g/dl	12.0 - 15.0	
PACKED CELL VOLUME(PCV)	37.8	%	36.0 - 46.0	
MCV	100.5 H	fl	82 - 92	
MCH	33.2 H	pg	27 - 32	
MCHC	33.1	g/dl	32 - 36	
RBC COUNT	3.76 L	millions/cu.mm	3.80 - 4.80	
TLC (TOTAL WBC COUNT)	5.63	10^3/ uL	4 - 10	
DIFFERENTIAL LEUCOCYTE COUNT				
NEUTROPHILS	59.6	%	40 - 80	
LYMPHOCYTE	32.3	%	20 - 40	
EOSINOPHILS	2.3	%	1 - 6	
BASOPHIL	0.5 L	%	1 - 2	
MONOCYTES	5.3	%	2 - 10	
PLATELET COUNT	3.80	lakh/cumm	1.500 - 4.500	

HAEMOGLOBIN :- Method:-SLS Hemoglobin Methodology by Cell Counter. Interpretation:-Low-Anemia, High-Polycythemia.

MCV :- Method: - Calculation by sysmex. MCH: - Method: - Calculation by sysmex.
MCHC: - Method: - Calculation bysysmex.

RBC COUNT :- Method:-Hydrodynamic focusing. Interpretation:-Low-Anemia, High-Polycythemia.

TLC (TOTAL WBC COUNT) :- Method: -Optical Detector block based on Flowcytometry. Interpretation: -High-Leucocytosis, Low-Leucopenia.

NEUTROPHILS :- Method: Optical detector block based on Flowcytometry LYMPHOCYTS :- Method: Optical detector block based on Flowcytometry EOSINOPHILS :- Method: Optical detector block based on Flowcytometry MONOCYTES :- Method: Optical detector block based on Flowcytometry

BASOPHIL :- Method: Optical detector block based on Flowcytometry PLATELET COUNT :- Method: Hydrodynamic focusing method. Interpretation: -Low-Thrombocytopenia, High-Thrombocytosis.

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE) 55 H

mm/1st hr

0 - 15

**RESULT ENTERED BY: SUNIL EHS** 

Dr. ABHINAY VERMA

**Patient Name** Lab No Mrs. KIRAN MEENA 4059434 26/10/2024 10:50AM UHID 40022528 **Collection Date** 26/10/2024 10:54AM Age/Gender **Receiving Date** 30 Yrs/Female **Report Date** O-OPD **IP/OP Location** 26/10/2024 6:23PM **Referred By** Dr. EHS CONSULTANT **Report Status** Final Mobile No. 9950555133

Method:-Modified Westergrens.
Interpretation:-Increased in infections, sepsis, and malignancy.

\*\*End Of Report\*\*

RESULT ENTERED BY : SUNIL EHS

## **DEPARTMENT OF RADIO DIAGNOSIS**

UHID / IP NO	40022528 (43046)	RISNo./Status:	4059434/
Patient Name:	Mrs. KIRAN MEENA	Age/Gender:	30 Y/F
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No :	26/10/2024 10:35AM/ OPSCR24- 25/25213	Scan Date :	
Report Date :	26/10/2024 12:01PM	<b>Company Name:</b>	Mediwheel - Arcofemi Health Care Ltd.

#### **ULTRASOUND STUDY OF WHOLE ABDOMEN**

Liver: Normal in size & echotexture. No obvious significant focal parenchymal mass lesion

noted. Intrahepatic biliary radicals are not dilated. Portal vein is normal.

**Gall Bladder:** Lumen is clear. Wall thickness is normal. CBD is normal.

**Pancreas:** Normal in size & echotexture.

**Spleen:** Normal in size & echotexture. No focal lesion seen.

Right Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or obstructive

calculus noted.

Left Kidney: Normal in shape, size & location. Echotexture is normal. Corticomedullary

differentiation is maintained. No evidence of significant hydronephrosis or obstructive

calculus noted.

Urinary Bladder: Normal in size, shape & volume. No obvious calculus or mass lesion is seen. Wall

thickness is normal.

**Uterus:** Normal in size, shape & anteverted in position. Endometrial thickness is normal.

Endometrial cavity is empty. No mass lesion is seen. Cervix is normal.

**Both ovaries:** Bilateral ovaries are normal in size, shape & volume.

**Others:** No significant free fluid is seen in pelvic peritoneal cavity.

**IMPRESSION**: USG findings are suggestive of

• No significant sonographic abnormality noted.

Correlate clinically & with other related investigations.

DR. SURESH KUMAR SAINI RADIOLOGIST

MBBS, MD.

Reg. No. 22597, 36208.

Spretty -

# **DEPARTMENT OF CARDIOLOGY**

UHID / IP NO	40022528 (43046)	RISNo./Status:	4059434/
Patient Name:	Mrs. KIRAN MEENA	Age/Gender:	30 Y/F
Referred By:	Dr. EHS CONSULTANT	Ward/Bed No:	OPD
Bill Date/No :	26/10/2024 10:35AM/ OPSCR24- 25/25213	Scan Date :	
Report Date:	26/10/2024 11:45AM	<b>Company Name:</b>	Final

REFERRAL REASON: HEALTH CHECKUP

## 2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

#### **M MODE DIMENSIONS: -**

Normal Normal								
IVSD	9.9	6-12mm			LVIDS	27.6	20-40mm	
LVIDD	44.9	32-57mm			LVPWS	15.9	mm	
LVPWD	9.9		6-1	2mm		AO	24.0	19-37mm
IVSS	15.9		1	mm		LA	30.8	19-40mm
LVEF	60-62		>:	55%		RA	•	mm
	DOPPLEI	R MEA	SUREM	IENTS &	& CALC	ULATIONS	<u>:</u>	
STRUCTURE	MORPHOLOGY	VELOCITY (m/s)			GRADIENT		REGURGITATION	
					(mmHg)			
MITRAL	NORMAL	E	0.76	e'	-	-		NIL
VALVE		A	0.53	E/e' -				
TRICUSPID	NORMAL		E	0.	52	-		NIL
VALVE				0	(0	-		
			A	0.0	08			
AORTIC	NORMAL	1.40			-		NIL	
VALVE								
PULMONARY	NORMAL	0.96					NIL	
VALVE						-		

## **COMMENTS & CONCLUSION: -**

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 60-62%
- NORMAL LV SYSTOLIC FUNCTION
- NORMAL LV DIASTOLIC FUNCTION
- ALL CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

#### **IMPRESSION: - NORMAL BI VENTRICULAR FUNCTIONS**

DR SUPRIY JAIN MBBS, M.D., D.M. (CARDIOLOGY) DIRECTOR & INCHARGE CARDIOLOGY DR MEGHRAJ MEENA MBBS, SONOLOGIST FICC, CONSULTANT PREV. CARDIOLOGY & INCHARGE CCU DR ROOPAM SHARMA MBBS, PGDCC, FIAE CONSULTANT & INCHARGE EMERGENCY, PREV. CARDIOLOGY(NIC) & WELLNESS CENTER